论文部分内容阅读
目的研究喘可治注射液联合重组人干扰素α1β雾化吸入治疗呼吸道疾病的刺激性和不良反应,考察药物联合作用及雾化吸入过程对豚鼠肺指数、气管、食管及肺等器官组织形态学的影响。方法豚鼠40只随机分为空白对照组(生理盐水)、阳性组(注射用重组人干扰素α1β)、喘可治组、联合给药组(喘可治注射液联合注射用重组人干扰素α1β)。雾化吸入给药,每天1次,连续给药7天。末次给药1 h后检测豚鼠肺指数,以及豚鼠肺、气管、食管的组织形态变化。结果与空白对照组比,阳性组、喘可治组、联合给药组豚鼠的一般情况均正常;肺指数无差异,均为0.69%左右;组织切片染色结果显示各组织未见异常病变。结论喘可治注射液联合重组人干扰素α1β雾化吸入给药刺激性小,联合给药雾化吸入7天对豚鼠肺指数及气管、食管、肺等器官组织形态学均无明显影响。
OBJECTIVE To study the irritation and adverse reactions of Chuankezhi injection combined with recombinant human interferon α1β aerosol inhalation in the treatment of respiratory diseases and to study the effects of drug combination and atomization inhalation on the lung tissue such as lung index, trachea, esophagus and lung Impact. Methods Forty guinea pigs were randomly divided into blank control group (normal saline), positive group (recombinant human interferon α1β for injection), Chuankezhi group and combined treatment group (Chuankezhi injection combined with recombinant human interferon α1β ). Inhaled inhalation, 1 day, continuous administration of 7 days. 1 h after the last administration, the guinea pig lung index and the lung, trachea and esophagus were observed. Results Compared with the blank control group, the positive condition, the asthma treatment group and the combined administration group were all normal. The lung index was no difference, both of which were about 0.69%. The histological sections showed no abnormal lesions in each tissue. Conclusion Chuankezhi injection combined with recombinant human interferon α1β aerosol inhalation is less irritating. Combined inhalation for 7 days has no significant effect on lung index and tracheal, esophageal and pulmonary organ histomorphology in guinea pigs.